101 related articles for article (PubMed ID: 21438527)
1. Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
Giannetti AM; Wong H; Dijkgraaf GJ; Dueber EC; Ortwine DF; Bravo BJ; Gould SE; Plise EG; Lum BL; Malhi V; Graham RA
J Med Chem; 2011 Apr; 54(8):2592-601. PubMed ID: 21438527
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding.
Graham RA; Lum BL; Cheeti S; Jin JY; Jorga K; Von Hoff DD; Rudin CM; Reddy JC; Low JA; Lorusso PM
Clin Cancer Res; 2011 Apr; 17(8):2512-20. PubMed ID: 21300760
[TBL] [Abstract][Full Text] [Related]
3. Absorption, distribution, metabolism, and excretion of [¹⁴C]GDC-0449 (vismodegib), an orally active hedgehog pathway inhibitor, in rats and dogs: a unique metabolic pathway via pyridine ring opening.
Yue Q; Chen YH; Mulder T; Deese A; Takahashi R; Rudewicz PJ; Reynolds M; Solon E; Hop CE; Wong H; Khojasteh SC
Drug Metab Dispos; 2011 Jun; 39(6):952-65. PubMed ID: 21363998
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.
Lorusso PM; Jimeno A; Dy G; Adjei A; Berlin J; Leichman L; Low JA; Colburn D; Chang I; Cheeti S; Jin JY; Graham RA
Clin Cancer Res; 2011 Sep; 17(17):5774-82. PubMed ID: 21753154
[TBL] [Abstract][Full Text] [Related]
5. A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry.
Graham RA; Lum BL; Morrison G; Chang I; Jorga K; Dean B; Shin YG; Yue Q; Mulder T; Malhi V; Xie M; Low JA; Hop CE
Drug Metab Dispos; 2011 Aug; 39(8):1460-7. PubMed ID: 21602311
[TBL] [Abstract][Full Text] [Related]
6. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
Wong H; Chen JZ; Chou B; Halladay JS; Kenny JR; La H; Marsters JC; Plise E; Rudewicz PJ; Robarge K; Shin Y; Wong S; Zhang C; Khojasteh SC
Xenobiotica; 2009 Nov; 39(11):850-61. PubMed ID: 19845436
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.
Wong H; Alicke B; West KA; Pacheco P; La H; Januario T; Yauch RL; de Sauvage FJ; Gould SE
Clin Cancer Res; 2011 Jul; 17(14):4682-92. PubMed ID: 21610148
[TBL] [Abstract][Full Text] [Related]
8. Interplay of dissolution, solubility, and nonsink permeation determines the oral absorption of the Hedgehog pathway inhibitor GDC-0449 in dogs: an investigation using preclinical studies and physiologically based pharmacokinetic modeling.
Wong H; Theil FP; Cui Y; Marsters JC; Khojasteh SC; Vernillet L; La H; Song X; Wang H; Morinello EJ; Deng Y; Hop CE
Drug Metab Dispos; 2010 Jul; 38(7):1029-38. PubMed ID: 20406853
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Hedgehog pathway in cancer: can the spines be smoothened?
Ailles L; Siu LL
Clin Cancer Res; 2011 Apr; 17(8):2071-3. PubMed ID: 21367749
[TBL] [Abstract][Full Text] [Related]
10. Determination of GDC-0449, a small-molecule inhibitor of the Hedgehog signaling pathway, in human plasma by solid phase extraction-liquid chromatographic-tandem mass spectrometry.
Ding X; Chou B; Graham RA; Cheeti S; Percey S; Matassa LC; Reuschel SA; Meng M; Liu S; Voelker T; Lum BL; Rudewicz PJ; Hop CE
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Mar; 878(9-10):785-90. PubMed ID: 20172765
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of deuterated Vismodegib for improving pharmacokinetic properties.
Wang F; Jiang H; Deng Y; Yu J; Zhan M; Zhao L; Chen Y
Bioorg Med Chem Lett; 2018 Aug; 28(14):2399-2402. PubMed ID: 29929879
[TBL] [Abstract][Full Text] [Related]
12. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
Cirrone F; Harris CS
Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy.
Scales SJ; de Sauvage FJ
Trends Pharmacol Sci; 2009 Jun; 30(6):303-12. PubMed ID: 19443052
[TBL] [Abstract][Full Text] [Related]
14. GDC-0449-a potent inhibitor of the hedgehog pathway.
Robarge KD; Brunton SA; Castanedo GM; Cui Y; Dina MS; Goldsmith R; Gould SE; Guichert O; Gunzner JL; Halladay J; Jia W; Khojasteh C; Koehler MF; Kotkow K; La H; Lalonde RL; Lau K; Lee L; Marshall D; Marsters JC; Murray LJ; Qian C; Rubin LL; Salphati L; Stanley MS; Stibbard JH; Sutherlin DP; Ubhayaker S; Wang S; Wong S; Xie M
Bioorg Med Chem Lett; 2009 Oct; 19(19):5576-81. PubMed ID: 19716296
[TBL] [Abstract][Full Text] [Related]
15. Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects.
Graham RA; Hop CE; Borin MT; Lum BL; Colburn D; Chang I; Shin YG; Malhi V; Low JA; Dresser MJ
Br J Clin Pharmacol; 2012 Nov; 74(5):788-96. PubMed ID: 22458643
[TBL] [Abstract][Full Text] [Related]
16. Embryofetal development study of vismodegib, a hedgehog pathway inhibitor, in rats.
Morinello E; Pignatello M; Villabruna L; Goelzer P; Bürgin H
Birth Defects Res B Dev Reprod Toxicol; 2014 Apr; 101(2):135-43. PubMed ID: 24692404
[TBL] [Abstract][Full Text] [Related]
17. Vismodegib: a promising drug in the treatment of basal cell carcinomas.
Dirix L; Rutten A
Future Oncol; 2012 Aug; 8(8):915-28. PubMed ID: 22894666
[TBL] [Abstract][Full Text] [Related]
18. Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the γ-secretase inhibitor RO4929097.
Wu J; Lorusso PM; Matherly LH; Li J
Clin Cancer Res; 2012 Apr; 18(7):2066-79. PubMed ID: 22351688
[TBL] [Abstract][Full Text] [Related]
19. Investigations into the mechanisms of pyridine ring cleavage in vismodegib.
Khojasteh SC; Yue Q; Ma S; Castanedo G; Chen JZ; Lyssikatos J; Mulder T; Takahashi R; Ly J; Messick K; Jia W; Liu L; Hop CE; Wong H
Drug Metab Dispos; 2014 Mar; 42(3):343-51. PubMed ID: 24389420
[TBL] [Abstract][Full Text] [Related]
20. USP28 and USP25 are downregulated by Vismodegib in vitro and in colorectal cancer cell lines.
Wang H; Meng Q; Ding Y; Xiong M; Zhu M; Yang Y; Su H; Gu L; Xu Y; Shi L; Zhou H; Zhang N
FEBS J; 2021 Feb; 288(4):1325-1342. PubMed ID: 32578360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
